New combo therapy shows promise for EGFR-Mutant lung cancer
NCT ID NCT02759614
First seen Mar 18, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study tested whether adding bevacizumab to erlotinib helps people with a specific type of advanced lung cancer (non-small cell lung cancer with EGFR mutations) live longer without their cancer getting worse. About 311 Chinese patients took part. The goal was to see if the combination worked better than erlotinib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.